Act(os) against cancer: Pioglitazone (trade name: Actos), an anti-diabetic drug, increases the expression of tumor suppressors genes, such as PIAS3, IGFBP3, p53,  p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 5/September/2018, 11.14 am

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: PCGF2/Mel-18 increases the expression of tumor suppressors genes, such as  PTPN14, Rb, p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 5/September/2018, 11.07 am
September 5, 2018
Molecular therapy for an enhanced, extended, and healthy lifespan: Lobeglitazone (trade name: Dovie), an anti-hyperglycemic agent, increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 7/September/2018, 11.59 pm
September 7, 2018
Show all

Teacher’s day special

*********

We wish everyone a happy Teacher’s day. On this special occasion, we are happy to announce that ideas posted today (05/September/2017) will be available to the use of Scientists/Professors/Physicians/Researchers for free. So, there will be no terms and conditions, for the ideas posted today (05/September/2018). Each idea posted will be served first-come, first served basis.

Write to info@genomediscovery.org for more details.

Dr L Boominathan PhD

CEO & CSO, GBMD

___________________________________________________________________________________________________________________________

 

From Significance of the study to Public health relevance

Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant p53-overexpressing tumors; (4) cancer causes the highest economic loss compared to all the known causes of death worldwide; and (5) cancer causes the considerable economic loss worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; and (iii) a way to effectively treat and stall metastatic progression and relapse of mutant p53-overexpressing human cancers.


From therapeutic strategy to Research Findings:

(i) Therapeutic strategy: 

This study suggests a therapeutic strategy for stalling the progression of p53-deficient/deleted or mutant-p53 expressing metastatic cancers. By activating tumor suppressor p53’s unmutated “homologous protein such as TAp73/p63” in p53-deficient or mutant-p53 expressing metastatic cancer cells, one can stall their progression.

(ii) Research findings:  

This study suggests that anti-diabetic drug Pioglitazone may function as an anti-cancer drug in mutant p53 expressing human cancers. Pioglitazone (Actos) has been shown to function as a tumor suppressor in a number of cancers. However, the mechanism of action remains largely unknown.

Figure 1. Mechanistic insight into how  Pioglitazone (Actos) functions as an anticancer/antimetastatic agent in mutant p53-expressing tumors.  Pioglitazone (Actos),  by activating tumor/metastasis suppressor genes, such as PIAS3, IGFBP3, p53, TAp63, TAp73, INK4a/ARF and others, in metastatic tumors, it may inhibit the progression of mutant-p53 expressing human cancers.

Figure 2. Pioglitazone (Actos) functions as an anti-tumor/metastatic agent through induction of tumor/metastatic suppressor genes, such as  PIAS3, IGFBP3, p53, TAp63, TAp73, and INK4aThis study suggests that PCGF2/Mel-18 may function as an anti-cancer/metastasis agent by increasing the expression a number of tumor/metastasis suppressor genes.

This study suggests that Pioglitazone (Actos), by increasing the expression of its target gene, it may increase the expression of tumor/metastasis suppressors genes, such as PIAS3, IGFBP3, p53, TA-p73, p53, INK4a/ARF and others. Thereby, it may inhibit the migration and invasion of metastatic cancer cells expressing mutant-p53 (figure1).

 


Therapeutic opportunity:

Given the ability of Pioglitazone (Actos) to induce the expression of a number of tumor/metastasis suppressor genes, it may be used, either alone or in combination with other anticancer drugs, to inhibit the progression of p53-mutated invasive metastatic tumors. Taken together, this study suggests, for the first time, that oncologists may consider treating metastatic cancer patients with Pioglitazone (Actos), as it may stall the progression of advanced metastatic cancers. (figure 2).


Details of the research findings

Idea Proposed/Formulated by Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $300#

Undisclosed mechanistic information: How Pioglitazone (Actos) increases the expression of tumor suppressor genes, such as PIAS3, IGFBP3, p53,  p53, TAp63, TAp73, INK4a/ARF and others,  in mutant p53 expressing cancer cells?

For purchase and payment details, you may reach us at admin@genomediscovery.org

#Research cooperation

[easy_payment currency=”USD”]

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors:


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Act(os) against cancer: Pioglitazone (trade name: Actos), an anti-diabetic drug, increases the expression of tumor suppressors genes, such as PIAS3, IGFBP3, p53,  p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 5/September/2018, 11.52 am, Genome-2-Biomedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.